Survodutide (BI 456906)

Survodutide is an investigational peptide co-agonist activating both the GLP-1 receptor (driving appetite suppression and glycemic effects) and the glucagon receptor (driving energy expenditure and lipid mobilization).

Survodutide was originally discovered at Zealand Pharma and is being co-developed with Boehringer Ingelheim. It was designed as a balanced dual GLP-1 / glucagon receptor co-agonist, adding glucagon-driven energy expenditure to the GLP-1 appetite suppression mechanism, similar in concept to retatrutide but without GIP activity.

The dual-agonist concept asks the glucagon-receptor arm to balance glucose tolerability against the appetite-suppressing GLP-1 arm. Engineered receptor selectivity ratios produce net glycemic benefit while retaining the metabolic-rate effects of glucagon.^[1]

Designed for once-weekly subcutaneous dosing, survodutide's pharmacokinetic profile in early-phase studies has been compatible with extended-interval dosing.

The peer-reviewed literature on Survodutide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity, supported claims, claims that look promising but need more data, and claims that outrun the science.

Phase 2/3 trials use weekly subcutaneous injection with stepped dose escalation, similar in pattern to other incretin co-agonists.

Survodutide is a leading next-generation incretin program with a particularly strong narrative for liver disease. The Phase 3 obesity readouts landed below tirzepatide's published results and came with high discontinuation rates, which points toward a distinctive role in liver disease rather than a place at the top of the weight-loss tier.

Phase 3 SYNCHRONIZE results (2026)

Boehringer Ingelheim and Zealand Pharma reported topline Phase 3 results on April 28, 2026, and presented the full data at the American Diabetes Association Scientific Sessions in June 2026. SYNCHRONIZE-1 was published simultaneously in the New England Journal of Medicine, and SYNCHRONIZE-MASLD in Nature Medicine.

• SYNCHRONIZE-1 — in adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% average weight loss at 76 weeks on the efficacy estimand, against 3.2% on placebo (p<0.0001).
• SYNCHRONIZE-MASLD — reported substantial reductions in liver fat alongside weight loss, consistent with the glucagon arm's hepatic-metabolism rationale.
• SYNCHRONIZE-2 (presented at EASD and published in the New England Journal of Medicine, October 2026) — in 755 adults with obesity and type 2 diabetes, the high dose produced 13.1% weight loss at 76 weeks vs 3.1% on placebo in the company's efficacy analysis (9.8% vs 3.9% in the NEJM treatment-policy analysis), with an HbA1c fall of 1.21 points. Discontinuation for adverse events was reported at 26%, and vomiting at 39%.^[4]

Two things are worth holding in view when comparing this with other agents. The 16.6% figure sits below the headline numbers reported for tirzepatide and retatrutide, but no head-to-head trial against semaglutide or tirzepatide has been run, so cross-trial comparison is unreliable. And the MASLD data is the more distinctive result: the glucagon component targets liver-fat biology in a way pure incretin agonists do not.